Can you take Ozempic with Vyvgart?

The semaglutide in Ozempic has a moderate potential interaction with Dehydration.

There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.

The semaglutide in Ozempic has a moderate potential interaction with Diabetic Retinopathy.

Patients with history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment with semaglutide. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.

The semaglutide in Ozempic has a moderate potential interaction with Diarrhea.

There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.

The semaglutide in Ozempic has a moderate potential interaction with Gastroparesis.

There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.

The efgartigimod alfa in Vyvgart has a moderate potential interaction with Infection.

Efgartigimod alfa may increase the risk of infection. Clinical studies have shown patients receiving efgartigimod alfa had below normal levels of white blood cell counts, lymphocytes, and neutrophils compared to placebo. Treatment with efgartigimod alfa should be delayed in patients with an active infection until the infection is resolved. During treatment, monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding efgartigimod alfa until the infection has resolved.

The semaglutide in Ozempic has a major potential interaction with Multiple Endocrine Neoplasia Type II.

The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. It is recommended to counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.

The efgartigimod alfa in Vyvgart has a moderate potential interaction with Renal Dysfunction.

There are insufficient data to evaluate the impact of moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m2) and severe renal impairment (eGFR less than 30 mL/min/1.73 m2) on the pharmacokinetic parameters of efgartigimod alfa. No dose adjustment is needed for patients with mild renal impairment.

The semaglutide in Ozempic has a major potential interaction with Thyroid Tumor.

The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. It is recommended to counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.

The efgartigimod alfa in Vyvgart has a moderate potential interaction with Vaccination.

Vaccination with live-attenuated or live vaccines is not recommended during treatment with efgartigimod alfa because efgartigimod alfa causes a reduction in IgG levels. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating a new treatment cycle.

The semaglutide in Ozempic has a moderate potential interaction with Vomiting.

There have been postmarketing reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with semaglutide. The majority of events occurred in patients with gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea); therefore, semaglutide is not recommended in patients with severe gastroparesis. It is recommended to monitor renal function in patients reporting adverse reactions to semaglutide that may lead to volume depletion, especially when initiating or escalating doses of semaglutide.